English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The appearance of new antihypertensive agents has not led to an increase in the frequency of achieving the target AP level in AG monotherapy.1-3 This fact is caused by the emphasis on combined therapy of AG. When choosing a drug for combined therapy of HA it is necessary to take into account the presence of risk factors, lesions of target organs, and associated clinical conditions. 4,5,6 It has been revealed that certain antihypertensive medications of arterial pressure reduction can also influence metabolism. Mohsonidin, sympatholytic, and agonist of imidazoline receptors of the central nervous system is an effective drug used to treat arterial hypertension.5,6 Several clinical studies have shown the efficacy of moxonidine in treating AG, which was comparable with the efficacy of other modern antihypertensive drugs. Clinical studies presented in foreign literature indicate AD correction and cardioprotective effect when using this drug.7,8,9 There are also data on the reduction of insulin resistance when using this drug. 10,11

international journal of current research and review

Study of Cardiovascular Risk Prediction in Patients with Type 2 Diabetes with Arterial Hypertension after Combined Hypotensive Therapy of Enalapril with Moxonidine